Enquiry

Technical data sheet (TDS) / Specifications sheet

DOTA-(Tyr3)-octreotate, puriss, 97%+

: DOTATATE, DOTA-octreotate, oxodotreotide, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraaza-cyclododec-1-yl]acetyl]- D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L- cysteinyl-,cyclic(2->7) dusulfide, DOTA-octreotate, DOTA-(Tyr3)-octreotate, 2,2',2''-(10-(2-(((R)-1-(((4R,7S,10S,13R,16S,19R)-13-((1H-Indol-3-yl)methyl)-10-(4-aminobutyl)-4-(((1S,2R)-1-carboxy-2-hydroxypropyl)carbamoyl)-16-(4-hydroxybenzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid xacetate salt

: D 4518

: GMP

: C65H90N14O19S2

: 97%+

: 1435.63

: Precursor for radiolabelled DOTA-TOC Ligand for somatostatin receptors

: D 4518 (OTTO) DOTATATE acetate, puriss, 97%+ GMP - used in chemical research.


Properties

: 97%+

: Powder

: Colourless to off white

: ≥80%

: ≤7.0%

: 0 - 4°C


Safety Information

Safety Information for this product is unavailable at this time.


PackingsPrice (INR)
50 μg POR
100 μg POR
250 μg POR
1 mg POR